Does Vanzacaftor Tezacaftor And Deutivacaftor Interact with Mao Inhibitors?
CDI records a major classification for Vanzacaftor Tezacaftor And Deutivacaftor and Mao Inhibitors. The stored summary is: Reduce ALYFTREK dosage with concomitant use. CYP3A inhibitors increase vanzacaftor, tezacaftor, and deutivacaftor exposure, which may increase risk of adverse reactions. The mechanism involves cyp3a inhibition increases substrate exposure. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Major
- Vanzacaftor Tezacaftor And Deutivacaftor Class
- Cystic Fibrosis Transmembrane Conductance Regulator Potentiator
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
CYP3A inhibition increases substrate exposure
What To Tell Your Doctor or Pharmacist
If you are taking Vanzacaftor Tezacaftor And Deutivacaftor and your doctor is considering prescribing Mao Inhibitors (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider